Previous 10 | Next 10 |
NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics , Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), and Mis...
Conference Call and Webcast at 9 a.m. Eastern Time on August 14, 2019 NEWTOWN, Pa., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a fo...
Gainers : Anika Therapeutics (NASDAQ: ANIK ) +34% . TCR2 Therapeutics (NASDAQ: TCRR ) +30% . Diebold Nixdorf (NYSE: DBD ) +26% . EDAP TMS (NASDAQ: EDAP ) +20% . Hovnanian (NYSE: HOV ) +18%. NETGEAR (NASDAQ: NTGR ) +16% . Meritage Homes (NYSE: MTH ) +16% . Empire Resorts (NASDA...
NEWTOWN, Pa., June 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced two presentati...
NEWTOWN, Pa., May 28, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it will be...
Deals and Financings MGI Tech Company, a Shenzhen maker of gene sequencing machines, announced it closed its first funding round with more than $200 million. MGI is a subsidiary of BGI, China's largest sequencing services provider. Founded in 2016, MGI is dedicated to offering a China altern...
Onconova Therapeutics, Inc. (ONTX) Q1 2019 Results Earnings Conference Call May 14, 2019, 09:00 AM ET Company Participants Avi Oler - VP, Corporate Development, General Counsel Steve Fruchtman - President and CEO Ric Woodman - Chief Medical Officer Mark Guerin - CFO Conferen...
Onconova Therapeutics (NASDAQ: ONTX ): Q1 GAAP EPS of -$1.29 misses by $0.26 . More news on: Onconova Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEWTOWN, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS), today ...
Amber Road (NYSE: AMBR ) +26% on being acquired by E2open. More news on: Amber Road, Inc., Onconova Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Onconova Therapeutics Inc. Company Name:
ONTX Stock Symbol:
NASDAQ Market:
Onconova Therapeutics Inc. Website:
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines Funding expected to ...
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onco...
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines Funding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; tra...